Teleflex Incorporated (FRA:TBH)
Germany · Delayed Price · Currency is EUR | Market Cap | 5.10B +15.6% |
| Revenue (ttm) | 1.84B +54.6% |
| Net Income | -874.93M |
| EPS | -19.78 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 18.04 |
| Dividend | 1.17 (1.01%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | n/a |
| Open | 114.10 |
| Previous Close | 115.70 |
| Day's Range | 114.10 - 114.10 |
| 52-Week Range | 85.00 - 120.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and col... [Read more]
News
Teleflex initiated with a Neutral at UBS
UBS analyst Patrick Wood initiated coverage of Teleflex (TFX) with a Neutral rating and $145 price target
Teleflex Announces Second Quarter 2026 Earnings Conference Call Information
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on...
Teleflex awarded national central venous access agreement with Premier
Teleflex Incorporated (TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc (PINC). Effective July 1, 2026, the new agreement allows Premier...
Teleflex Awarded National Central Venous Access Agreement with Premier, Inc.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc. Effective July 1, 2026, the ...
Teleflex price target raised to $145 from $140 at Mizuho
Mizuho raised the firm’s price target on Teleflex (TFX) to $145 from $140 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical device and…
Teleflex initiated with an Outperform at BMO Capital
As previously reported, BMO Capital analyst Vik Chopra initiated coverage of Teleflex (TFX) with an Outperform rating and $159 price target Consensus “hasn’t fully captured” the 2027 EPS bridge and…
Teleflex initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Teleflex (TFX) with an Outperform rating and $159 price target
Teleflex Publishes 2025 Global Impact Report
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines r...
Teleflex begins enrollment in BIOMAG-III Study
Teleflex (TFX) announced the beginning of enrollment in the BIOMAG-III Study, a landmark global study evaluating the Freesolve Resorbable Magnesium Scaffold.
Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (NCT07258290), a...
Teleflex’s Freesolve RMS shows long-term safety in four-year study
Teleflex (TFX) announced the four-year follow-up data from the First-in-Human BIOMAG-I Clinical Study presented at the EuroPCR conference in Paris. Enrolling 116 patients, the study continues to demon...
Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinic...
Teleflex upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Teleflex (TFX) to Overweight from Neutral with a price target of $160, up from $140, following a transfer of coverage. The firm sees upside to the current…
Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due ...
Teleflex announces private offering of $500M of senior notes
Teleflex (TFX) Incorporated announced the commencement of a private offering of $500M aggregate principal amount of senior notes due 2032, subject to market and other conditions. The interest rate and...
Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032...
Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical da...
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...
Teleflex price target raised to $150 from $128 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on Teleflex (TFX) to $150 from $128 and keeps an Outperform rating on the shares. The Q1 results were “encouraging,”…
Teleflex price target raised to $140 from $135 at Mizuho
Mizuho raised the firm’s price target on Teleflex (TFX) to $140 from $135 and keeps a Neutral rating on the shares.
Teleflex upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Shagun Singh upgraded Teleflex (TFX) to Outperform from Sector Perform with a price target of $155, up from $135. The firm says the company is making progress…
Teleflex reports Q1 adjusted EPS $1.39, consensus $1.22
Reports Q1 revenue $548.3M, consensus $537.59M. “Our Q1 performance reflects disciplined execution and meaningful progress against our transformation plan,” said CEO Stuart Randle. “We delivered a str...
Teleflex still sees 2026 adjusted EPS view $6.25-$6.55, consensus $6.72
Still sees 2026 revenue growth view of 14.4%-15.4% from 2025 revenue of $1.98B, consensus $2.29B.
Teleflex Earnings Call Transcript: Q1 2026
Q1 2026 saw 32.3% revenue growth (GAAP) and 5.1% pro forma adjusted growth, with adjusted EPS down 3.5% year-over-year. Strategic divestitures and restructuring are on track, with significant margin and EPS improvements expected in 2027.
Teleflex Earnings release: Q1 2026
Teleflex released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.